重大公告
OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3
Date of occurrence: June 01, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding …
Announcement of explanation on the first instance judgment of the civil action between the Company against “Next Magazine”
Parties to the legal matter: Plaintiff: OBI Pharma, Inc. Defendant: Next Digital Ltd., Hong Kong (”Next@Digital”) Name of the court or disposing agency: Taipei District …
Announcement of explanation on the Company’s criminal lawsuit against Next Magazine
Parties to the legal matter: OBI Pharma, Inc. Name of the court or disposing agency: Shihlin District Prosecutors Office, Taiwan Reference/case numbers of relevant documents: …
OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan
Date of occurrence of the event: April 6, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): …
The board of directors have resolved not to distribute dividends
Date of the board of directors resolution : 9 Mar 2017 (1) Appropriations of earnings in cash dividends to shareholders (NT$ per share): 0 (2) …